Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CC-486 alone and with carboplatin or nab-paclitaxel in relapsed or refractory solid tumors
NL-OMON39682Phase 1Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- May 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-486, carboplatin and paclitaxel in Nonhematologic neoplasms, transitional cell carcinoma (TCC), ovarian cancer and 9 more, sponsored by Celgene Corporation. Started May 2013; status: active, not recruiting.
02
Drugs
CC-486carboplatinpaclitaxel
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON39682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39682.